What are the terms of the new notes being issued?

The new issuance comprises $1.75 billion in aggregate principal amount of senior unsecured notes, split into three series: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055.

How does this debt issuance impact Biogen's financial obligations?

This issuance effectively replaces existing short-term debt (maturing in 2025) with longer-term debt obligations. While the principal amount remains $1.75 billion, the coupon rates on the new notes are generally higher than the maturing notes, indicating a potential increase in future interest expense, but with a significantly extended maturity.

Are there any protective clauses for investors in the new notes?

Yes, the notes contain a change-of-control provision. If a change of control event occurs under certain circumstances, Biogen may be required to offer to purchase these notes at 101% of their principal amount, plus accrued interest.

BIIB 8-K SEC Disclosure

01—Abstract

Summary

Summary of the 8-K filed May 12, 2025. Cited figures are marked; the original filing is the authoritative source.

Biogen Inc. (BIIB) announced the completion of a significant debt offering, successfully issuing and selling $1.75 billion^a in aggregate principal amount of senior unsecured notes on May 12, 2025.

This offering consists of three tranches: $400 million^b of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055. The company intends to use the net proceeds from this issuance, along with existing cash, to fully retire its outstanding $1.75 billion of 4.050% Senior Notes due 2025. This strategic refinancing aims to extend Biogen's debt maturity profile and potentially optimize its interest expense.

02—Key points

Key Highlights

Biogen Inc. raised $1.75 billion through a new issuance of senior unsecured notes.
The new debt consists of three tranches with varying maturities and coupon rates: 5.050% due 2031, 5.750% due 2035, and 6.450% due 2055.
The primary use of proceeds is to fully redeem the outstanding $1.75 billion of 4.050% Senior Notes due 2025.
This transaction effectively refinances the maturing debt, extending Biogen's debt maturity profile.
The notes were issued under an automatic shelf registration statement filed on May 1, 2025.
The notes include a change-of-control provision requiring a potential purchase offer at 101% of principal under certain circumstances.
The remaining proceeds, if any, will be used for working capital and general corporate purposes.

03—Questions

Frequently Asked Questions

What is the purpose of Biogen's new debt issuance?
Biogen issued $1.75 billion in new senior unsecured notes primarily to refinance its maturing $1.75 billion of 4.050% Senior Notes due 2025. This move extends the company's debt maturity profile and ensures continued access to capital.
What are the terms of the new notes being issued?
The new issuance comprises $1.75 billion in aggregate principal amount of senior unsecured notes, split into three series: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055.
How does this debt issuance impact Biogen's financial obligations?
This issuance effectively replaces existing short-term debt (maturing in 2025) with longer-term debt obligations. While the principal amount remains $1.75 billion, the coupon rates on the new notes are generally higher than the maturing notes, indicating a potential increase in future interest expense, but with a significantly extended maturity.
Are there any protective clauses for investors in the new notes?
Yes, the notes contain a change-of-control provision. If a change of control event occurs under certain circumstances, Biogen may be required to offer to purchase these notes at 101% of their principal amount, plus accrued interest.

04—Continue

← View all 8-K filings